Cykinso

Direct-to-consumer tests for intestinal microbiome profiling. Its flagship product Mykinso uses next-generation sequencing and proprietary bioinformatics for metagenomic profiling of the customer's stool sample. Users can purchase the fecal sample kit, register it online and mail the sample to the company. In addition, they are encouraged to fill in a lifestyle-related questionnaire that Cykinso plans to use in future research. Results can be viewed on the company website or the accompanying app Founded in 2014, headquartered in Shibuya, Japan. The company has raised $15.7M at the Series D stage backed by investors including Nitto Boseki, Nihonkai, REVIC, Innoh Associates, Yamanashi Chugin Management Consulting. Operating in Life Sciences > Genomics, Life Sciences > Clinical Genomics.